Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

A Randomized Clinical Trial Evaluating Tamoxifen In The Treatment Of Patients With Node-negative Breast Cancer Who Have Estrogen-receptor-positive Tumors.

B. Fisher, J. Costantino, C. Redmond, R. Poisson, D. Bowman, J. Couture, N. Dimitrov, N. Wolmark, D. L. Wickerham, E. Fisher
Published 1989 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
We conducted a randomized, double-blind, placebo-controlled trial of postoperative therapy with tamoxifen (10 mg twice a day) in 2644 patients with breast cancer, histologically negative axillary nodes, and estrogen-receptor-positive (greater than or equal to 10 fmol) tumors. No survival advantage was observed during four years of follow-up (92 percent for placebo vs. 93 percent for tamoxifen; P = 0.3). There was a significant prolongation of disease-free survival among women treated with tamoxifen, as compared with those receiving placebo (83 percent vs. 77 percent; P less than 0.00001). This advantage was observed in both the patients less than or equal to 49 years old (P = 0.0005) and those greater than or equal to 50 (P = 0.0008), particularly in the former, among whom the rate of treatment failure was reduced by 44 percent. Multivariate analysis indicated that all subgroups of patients benefited. Tamoxifen significantly reduced the rate of treatment failure at local and distant sites, tumors in the opposite breast, and the incidence of tumor recurrence after lumpectomy and breast irradiation. The benefit was attained with a low incidence of clinically appreciable toxic effects. The magnitude of the improvement obtained does not preclude the need for future trials in which patients given tamoxifen could serve as the control group in an evaluation of potentially better therapies. Tamoxifen treatment is justified in patients who meet the eligibility criteria of the present study and who refuse to participate in those trials. Since patients with tumors too small for conventional analysis of estrogen-receptor and progesterone-receptor concentrations were not eligible for this study, no information is available to indicate that such patients should receive tamoxifen.
This paper references

This paper is referenced by
NCCN Clinical Practice Guidelines in Oncology for Breast Cancer Risk Reduction
Elizabeth Pritchard (2010)
Homocisteína e cisteína séricas como marcadores epigenéticos de prognóstico e preditivos de resposta em tumores de mama
Luis Gustavo Raimundo (2014)
Genetic-based prediction of disease traits: prediction is very difficult, especially about the future†
S. Schrodi (2014)
Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins
S. Myhre (2013)
The development of endocrine therapy for women with breast cancer.
R. Sainsbury (2013)
Maintenance efficacy designs in psychiatry: Randomized discontinuation trials – enriched but not better
S. N. Ghaemi (2017)
A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer
M. Levine (2001)
Selective estrogen-receptor modulators.
F. Cosman (2003)
Endometrial Effects of SERMs
S. Palacios (2006)
Age, cancer and the risk of venous thromboembolism.
F. Fimognari (2005)
Opportunities in clinical trials adjuvant breast cancer
M. Friedman (1990)
MRI-Based Screen for Breast Cancer Patients Carrying a Breast Cancer Susceptibility Gene
M. Schnall (1997)
Oncotype DX RT-qPCR Assay for ER and PR Correlation With IHC: A Study of 3 Different Clones
T. Khoury (2015)
Systemic Therapy in Breast Cancer
J. Corry (2012)
Retinoids and tamoxifen in breast cancer chemoprevention
A. Costa (1993)
Non-Disseminated Breast Cancer
G. Fletcher (1993)
Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy.
E. Obedian (2000)
Another view of the tamoxifen trial
C. Kaufman (1999)
Management of ductal carcinoma in situ.
E. S. Hwang (1999)
Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women.
M. Moyad (2002)
Prognostic Factors in Breast Cancer
S. Masood (1997)
Oestrogen receptors and breast cancer
R. Elledge (1997)
Prognosis among African‐American women and white women with lymph node negative breast carcinoma
J. Dignam (1997)
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
B. Fisher (1996)
Tamoxifen in Postmenopausal Women
E. Robinson (1996)
DNA ploidy and the percentage of cells in S‐phase as prognostic factors for women with lymph node negative breast cancer
T. Witzig (1994)
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
R. Chlebowski (2002)
Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.
G. Cancello (2010)
Metabolites of Tamoxifen as the Basis of Drug Development
P. Maximov (2013)
Adjuvant therapy for node‐negative breast cancer: The use of prognostic factors in selecting patients
D. Winchester (1991)
Development of the 21-gene assay and its application in clinical practice and clinical trials.
J. Sparano (2008)
Role of adjuvant chemotherapy in male breast cancer
H. Patel (1989)
See more
Semantic Scholar Logo Some data provided by SemanticScholar